Notably, co-expression of transcription factors, TWIST1 and ZEB2, was associated with a poorer patient overall survival, particularly in cohorts without detectable lymph node metastasis, likely suggesting a clinical utility in identifying patients with poor survival for appropriate patient management. The gene discussed is ZEB2; the disease is metastatic malignant neoplasm in the lymph nodes.